Verma Nishant, Maiti Rituparna, Mishra Biswa Ranjan, Jha Menka, Jena Monalisa, Mishra Archana
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
J Neurosci Res. 2021 Jun;99(6):1618-1631. doi: 10.1002/jnr.24820. Epub 2021 Feb 27.
Epilepsy treatment is challenging because of multiple impediments like lack of efficacy of monotherapy, adverse drug reactions, and different comorbidities. Add-on therapy to first-line antiepileptics may be the option to overcome therapeutic hurdles. The present randomized, double-blind, add-on placebo-controlled clinical trial was conducted to evaluate the effect of add-on melatonin in the treatment of generalized epilepsy with generalized onset motor seizure in adults. The control group (n = 52) received add-on placebo, and the test group (n = 52) received add-on melatonin (3 mg/day) with valproate (20 mg/kg in two divided doses). Clinical evaluation of seizure frequency, Chalfont-National Hospital seizure severity scale (NHS3), Pittsburgh sleep quality index (PSQI), quality of life in epilepsy inventory, Epworth sleepiness scale (ESS), and biochemical estimation of serum neuron-specific enolase (NSE) and glutathione reductase were done at baseline and compared with follow-up at 8 weeks. Among 104 patients randomized [mean (SD) age of 27.6 (11.5); 84 (80.8%) male], 88 (84.6%) completed the trial. The responder rate and seizure-free rate in the test group were significantly (p = 0.006 and 0.034) higher than the control group. There was a significantly higher reduction in the frequency of seizures (p = 0.016) and NHS3 (-2.39; 95%CI: -4.56 to -0.21; p = 0.032) in the test group compared to the control group. Similarly, improvement in PSQI (-1.40; 95%CI: -2.64 to -0.15; p = 0.029) was significantly better in the test group. There was no significant difference in the change in ESS (p = 0.621) and quality of life scoring (p = 0.456) between the study groups. The decrease in serum NSE was significantly higher with the test group compared to the control group (-2.01; 95% CI: -3.74 to -0.27; p = 0.024). Add-on melatonin increased serum glutathione reductase significantly (p = 0.038), but there was no significant difference between the groups (p = 0.685). Add-on melatonin with valproate for generalized epilepsy with generalized onset motor seizures in adults can achieve a significantly better clinical outcome by reducing the seizure frequency, severity and attaining a better seizure-free rate in comparison to the control group.
癫痫治疗具有挑战性,因为存在多种障碍,如单药治疗缺乏疗效、药物不良反应以及不同的合并症。一线抗癫痫药物的附加疗法可能是克服治疗障碍的选择。本随机、双盲、附加安慰剂对照的临床试验旨在评估附加褪黑素治疗成人全身性癫痫伴全身性发作性运动性癫痫的效果。对照组(n = 52)接受附加安慰剂,试验组(n = 52)接受附加褪黑素(3毫克/天)与丙戊酸盐(20毫克/千克,分两次给药)。在基线时对癫痫发作频率、查尔方特-国家医院癫痫严重程度量表(NHS3)、匹兹堡睡眠质量指数(PSQI)、癫痫生活质量量表、爱泼华嗜睡量表(ESS)进行临床评估,并与8周后的随访结果进行比较。在104例随机分组的患者中[平均(标准差)年龄为27.6(11.5)岁;84例(80.8%)为男性],88例(84.6%)完成了试验。试验组的缓解率和无癫痫发作率显著高于对照组(p = 0.006和0.034)。与对照组相比,试验组的癫痫发作频率(p = 0.016)和NHS3(-2.39;95%置信区间:-4.56至-0.21;p = 0.032)显著降低。同样,试验组的PSQI改善情况(-1.40;95%置信区间:-2.64至-0.15;p = 0.029)明显更好。研究组之间的ESS变化(p = 0.621)和生活质量评分(p = 0.456)没有显著差异。与对照组相比,试验组血清神经元特异性烯醇化酶(NSE)的降低幅度显著更大(-2.01;95%置信区间:-3.74至-0.27;p = 0.024)。附加褪黑素显著增加了血清谷胱甘肽还原酶(p = 0.038),但两组之间没有显著差异(p = 0.685)。对于成人全身性癫痫伴全身性发作性运动性癫痫,附加褪黑素与丙戊酸盐联合使用与对照组相比,通过降低癫痫发作频率、严重程度并实现更好的无癫痫发作率,可取得显著更好的临床效果。